Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 7/20 | 0.69 |
| ▸ | TP53 | P04637 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
| ▸ | CCKBR | P32239 | 1/20 | 0.58 |
| ▸ | CTSL | P07711 | 2/20 | 0.58 |
| ▸ | PPARG | P37231 | 1/20 | 0.57 |
| ▸ | CTSB | P07858 | 1/20 | 0.57 |
| ▸ | CTSS | P25774 | 1/20 | 0.57 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16617077 | 1.00 | TACR1 (0.69) | TACR1TP53MAPTSMN1; SMN2CCKBR | |
| SCHEMBL16617625 | 0.96 | TACR1 (0.75) | TACR1TP53MAPTSMN1; SMN2CCKBR | |
| SCHEMBL16618111 | 0.93 | TACR1 (0.67) | TACR1CTSL | |
| SCHEMBL16618112 | 0.93 | TACR1 (0.67) | TACR1CTSL | |
| SCHEMBL16617278 | 0.92 | TACR1 (0.64) | TACR1MAPTCTSLCTSBCTSS | |
| SCHEMBL16618165 | 0.91 | TACR1 (0.67) | TACR1 | |
| SCHEMBL16617103 | 0.91 | MEN1 (0.66) | TACR1CTSLCTSBCTSSLNPEP | |
| SCHEMBL16618163 | 0.91 | TACR1 (0.67) | TACR1 | |
| SCHEMBL16617101 | 0.91 | MEN1 (0.66) | TACR1CTSLCTSBCTSSLNPEP | |
| SCHEMBL16617948 | 0.88 | TACR1 (0.67) | TACR1MAPTCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9593144-B2 | FPR1 antagonist derivatives and use thereof | CHANG GUNG UNIVERSITY (TW) | 2017-03-14 | — | — | US | disclosed |
| US-20150307548-A1 | FPR1 ANTAGONIST DERIVATIVES AND USE THEREOF | CHANG GUNG UNIVERSITY (TW) | 2015-10-29 | — | — | US | disclosed |
| US-20150099691-A1 | FPR1 ANTAGONIST DERIVATIVES AND USE THEREOF | CHANG GUNG UNIVERSITY (TW) | 2015-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150307548-A1 | FPR1 ANTAGONIST DERIVATIVES AND USE THEREOF | FPR1, FPR3, FPR2 | TACR1 84/4885TP53 3894/4885MAPT 4850/4885 |
| US-20150099691-A1 | FPR1 ANTAGONIST DERIVATIVES AND USE THEREOF | FPR1, FPR3, FPR2 | TACR1 84/4885TP53 3894/4885MAPT 4850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.